Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vertex Pharmaceuticals : Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $317 From $307, Reiterates Buy Rating

07/30/2021 | 11:55am EDT


© MT Newswires 2021
All news about VERTEX PHARMACEUTICALS
09/14VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Gl..
AQ
09/13VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Gl..
BU
09/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/09WALL STREET STOCK EXCHANGE : A step closer to tapering
09/09VERTEX PHARMACEUTICALS : Stifel Downgrades Vertex Pharmaceuticals to Hold from B..
MT
09/09ANALYST RECOMMENDATIONS : Boohoo, Boston Beer, Cisco Systems, Eversource, Frontl..
09/09Obsidian Therapeutics, Inc. announced that it has received $115 million in fu..
CI
09/08NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/07VERTEX PHARMACEUTICALS : Morgan Stanley Downgrades Vertex Pharmaceuticals to Und..
MT
08/26VERTEX PHARMACEUTICALS : Announces Publication in The New England Journal of Med..
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 269 M - -
Net income 2021 2 082 M - -
Net cash 2021 8 091 M - -
P/E ratio 2021 23,6x
Yield 2021 -
Capitalization 48 996 M 48 996 M -
EV / Sales 2021 5,63x
EV / Sales 2022 4,65x
Nbr of Employees 3 400
Free-Float 99,9%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 188,86 $
Average target price 260,91 $
Spread / Average Target 38,1%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-20.09%48 996
GILEAD SCIENCES, INC.23.17%89 973
BIONTECH SE335.78%85 800
REGENERON PHARMACEUTICALS34.96%67 787
WUXI APPTEC CO., LTD.28.41%64 886
BEIGENE, LTD.45.26%34 920